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Abstract: The five tautomers of the drug acyclovir (ACV) were determined and optimised 
at the MP2 and B3LYP quantum chemical levels of theory. The stability of the tautomers 
was correlated with different parameters. On the most stable tautomer N1 was carried out a 
comprehensive conformational analysis, and the whole conformational parameters (R, β, 
Φ, φ1, φ2, φ3, φ4, φ5) were studied as well as the NBO Natural atomic charges. The 
calculations were carried out with full relaxation of all geometrical parameters. The search 
located at least 78 stable structures within 8.5 kcal/mol electronic energy range of the 
global minimum, and classified in two groups according to the positive or negative value 
of the torsional angle ϕ1. In the nitrogen atoms and in the O2' and O5' oxygen atoms of the 
most stable conformer appear a higher reactivity than in the natural nucleoside 
deoxyguanosine. The solid state was simulated through a dimer and tetramer forms and the 
structural parameters were compared with the X-ray crystal data available. Several general 
conclusions were emphasized. 
Keywords: acyclovir; 9-(2-hydroxyethoxymethyl) guanine; tautomer; antiviral drug; 
conformational analysis; Zovirax 
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Acyclovir (ACV, 9-(2-hydroxyethoxymethyl) guanine, Zovirax [1,2], Figure 1), is a guanine 
derivative possessing antiviral activity and commonly used in the treatment of herpes. It is a potent 
antiviral agent that is used as a highly specific inhibitor of herpes viruses (HSV) types 1 and 2 [3–7].  
A series of new guanine base modified tricyclic analogues of ACV and ganciclovir were evaluated for 
activity against herpes simplex virus type 1 and 2, showing similar antiherpetic potency as the parent 
compounds ACV and ganciclovir [8]. The antiherpetic activity was found to be strongly dependent on 
the nature and esteric demands of the substituents in the 6 and/or 7 positions [9]. 
Figure 1. Molecular structure and definition of the torsional angles in tautomer N1 of acyclovir. 
 
Most persons who are infected with human immunodeficiency virus type (HIV-1) are also infected 
with herpes simplex type2 (HSV-2), which is associated with increased plasma and genital levels of 
HIV-1. Thus, it has been reported that ACV inhibits HIV upon human herpes virus (HHV) coinfection 
in tissue cultures. This activity was found to be correlated with the phosphorylation of the parent drug 
to the monophosphate form mediated by HHV-encoded kinase [10]. Recent studies show that ACV 
decreases the HIV-1 RN and suppress both viruses in coinfected tissues [11], with great impact on 
HIV and HSV-2 seropositive patients [12,13]. The treatment of ACV- resistant HSV infections [7,14] 
and tests for release it at oral therapeutic levels have been also reported [15]. 
As it is shown above, ACV has been extensively studied from the pharmaceutical and medical point 
of view. However, few studies appear on its molecular structure, only at low level [16], and to our 
knowledge, there is no data on its conformational characteristics by Density Functional Methods 
(DFT) or ab initio quantum chemical methods. Thus, it is one of the tasks of the present manuscript. 
Conformations of some derivatives of ACV with biological activities have been reported [17], as well 
as studies of complexes of ACV with several metals [18,19]. 
The tautomeric study of DNA structural components has a great interest today with numerous 
research publications [20,21]. The tautomeric equilibrium in ACV between the keto and enol forms 
has been observed from the UV/VIS spectra [22]. This equilibrium depends on the polarity of the 
solvent, and therefore, in water solution the keto form prevails, while in methylene chlorides it is the 
enol one. Thus, another goal of the present manuscript is to study the possible tautomers of ACV, and 
the determination of their % populations at room temperature and at 273.15 K. The stability of these 
tautomers and its dependence of different parameters is another point analyzed here. 
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Finally, from our understanding, would be interesting to calculate the different conformational 
possibilities of ACV and compare the results with the natural nucleoside deoxyguanosine (dG). This is 
the last goal of the present manuscript. An accurate knowledge of the different conformers of ACV, its 
charge distribution, inter- and intra-molecular interactions, solid structure, and flexibility would be an 
important help for the interpretation of drug-target interactions, as well as to design new antivirus. 
For this reason, the conformers of natural and analogues nucleosides have been analyzed by 
different authors. Now, an extensive theoretical study of the conformational preferences in ACV has 
been carried out with full relaxation of all geometric parameters, in an attempt to gain insights into 
molecular features responsible for activity. We will attempt to determine herein, if the various 
geometric features in ACV are correlated or interact with one another. We are also interested in 
whether alternative forms of hydrogen bonding make significant contributions to the conformational 
behavior of ACV. 
2. Computational Details 
Calculations were carried out by using the Becke exchange functional (B) [23], Becke’s  
three-parameter exchange functional (B3) [24], Handy’s OPTX modification of Becke’s exchange 
functional (O) [25,26] and the extended (X3) [27], in combination with the correlation functionals of 
Lee, Yang, and Parr (LYP) [28], and Perdew and Wang’s 1991 (PW91) [29]. B3LYP Density 
Functional method (DFT) is the most used today, and for this reason the majority of the calculations 
were carried out with it. 
All the methods appear implemented in the GAUSSIAN 03 program package [30]. The UNIX 
version with standard parameters of this package was used in the alpha computer of the Computational 
Centre from University Complutense of Madrid, in which all quantum chemical computations were 
performed. DFT methods provide adequate compromise between the desired accuracy and the heavy 
demands put on computer time and power. Different studies have shown that the data obtained with 
DFT methods are in good agreement with those obtained by expensive computational methods as  
MP2 [31–35]. Also they give good results in many studies on nucleosides and on drug design [36,37] 
and they predict vibrational frequencies of DNA bases better than HF and MP2 [38–42]. Moreover, 
because of the high size of ACV, MP2 calculations were only possible with the 6–31G(d) basis set for 
memory computer problems. However, we used the 6–31G(d,p) basis to calculate single point energies. 
The 3D Potential Energy Surface (PES) of this molecule was determined by rotation of the 
exocyclic and endocyclic torsional angles φ1 (equivalent to χ angle in nucleosides [43]), φ2, φ3, φ4  
and φ5. These dihedral angles were simultaneously hold fixed at values varying between 0° and 360° in 
steps of 60° in a first study. All other geometrical parameters were relaxed during these optimizations. 
78 optimized geometries were obtained in this step by minimizing the energy with respect to all 
geometrical parameters without imposing molecular symmetry constraints. Berny optimizations  
under the TIGHT criterion were used. Atomic charges were determined with the Natural NBO 
procedure [44]. 
Harmonic wavenumber computations were carried out at the same level of the respective 
optimization process and by the analytic evaluation of the second derivative of the energy with respect 
to nuclear displacement. Vibrational frequencies calculations were performed on all optimized 
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conformers to confirm that they corresponded to local minima. All optimized structures showed only 
positive harmonic vibrations (local energy minima). Relative energies were obtained by adding  
zero-point vibrational energies (ZPEs) to the total energy. For the calculation of the ZPEs, the 
frequencies were retained unscaled. The ΔG values were sums of electronic and thermal Free Energies. 
The conformational equilibrium at 298.15 K was evaluated by means of the Boltzmann distribution 
formula exp(−ΔG/kT), where ΔG is the relative Gibbs energy. 
3. Results and Discussion 
ACV has five possible tautomers (Figure 2), that were fully optimized at different levels of 
computation, Table 1. The most stable one corresponds to N1, and thus we have focused the study only 
in this tautomer. The remaining forms were left for future research. In the last two column of this 
Table is shown the % population of the different tautomers at 298.15 K and 273.15 K. At room 
temperature the largest population corresponds to tautomer N1 (48.1%). The second population is due 
to OHC tautomer (37.7%) and the third one is to OHT (14.3%). Tautomers N3 and N7 have very little 
population, less than 0.05%. 
Figure 2. Five tautomers described in acyclovir. 
 
N1 N3 N7 
OHC OHT 
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Table 1. The optimum stable tautomers calculated in acyclovir molecule at the levels: B3LYP/6-311++G(3df,pd) (values in bold);  
MP2/6-31G(d,p) (values in key); B3LYP/6-31G(d,p) (values in normal); O3LYP/6-31G(d,p) (values in brackets); B3PW91/6-31G(d,p) 
(values in parenthesis); B3LYP/cc-pVDZ (values in quotation marks) and B972/6-31G(d,p) (values in italic type). Torsional angles in degrees, 
dipole moments in debyes, distance R in Å, energy increments in kcal·mol−1 and population (%) at 298.15 K (P298.15) and at 273.15 K (P273.15). 


























































































































































































a ΔE = 0 = −811.214731 a.u. at B3LYP/6-311++G(3df,pd) level; b ΔE = 0 = −808.643998 a.u. at MP2/6-31G(d,p) level; c ΔE = 0 = −810.723396 a.u. at B3LYP/6-31G(d,p) level;  
d ΔG = 0 = −810.764701 a.u.; e ΔE = 0 = −810.449499 a.u. at O3LYP/6-31G(d,p) level; f ΔG = 0 = −810.490782 a.u.; g ΔE = 0 = −810.419555 a.u. at B3PW91/6-31G(d,p) level;  
h ΔG = 0 = −810.460766 a.u.; i ΔE = 0 = −810.760402 a.u. at B3LYP/cc-pVDZ level; j ΔG = 0 = −810.801662 a.u.; k ΔE = 0 = −810.444324 a.u. at B972/6-31G(d,p) level; 
l ΔG = 0 = −810.485454 a.u. 
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An analysis of the relative energies of these tautomers shows that they can be related to the dipole 
moment (μ) and to the torsional angle φ1, Figure 3. Thus, the least stable tautomer in the isolated state 
(N7) has the highest μ, i.e., it is the most stable in water solution. Other relations can be observed 
between ΔE and φ1. It is noted that tautomer N7 has the highest negative value of φ1 angle. 
Figure 3. Relationship/tendency observed between the relative electronic energy  
ΔE + ZPE correction of the different tautomers vs. (a) the dipole moment μ. and (b) the 
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3.1. Definition of the Conformational Angles  
The atomic description of tautomer N1 of ACV, as well as the most important exocyclic and 
endocyclic torsional angles, is defined in Figure 1. The conformation can be characterized by the 
following five torsional angles: (i) the torsional angle, φ1(C4-N9-C1'-O2'), which determines the two 
orientations of the base relative to the opened chain, denoted in the present manuscript as conformers 
A and B; (ii) The exocyclic torsional angle φ2 (N9-C1'-O2'-C3'); (iii) φ3 (C1'-O2'-C3'-C4') that 
determine the different folds of the chain; (iv) φ4 (O2'-C3'-C4'-O5') describing the O5'H orientation; 
and (v) the torsional angle φ5 (C3'-C4'-O5'-H5') that define the orientation of the hydroxyl hydrogen 
H5'. This φ5 angle has some similarities with the β angle of the nucleosides [43]. 
Considering the structure of the chain, that likes the structure of the sugar in the nucleosides, and in 
accordance to previous works [45], other three structural parameters were defined to fix the chain 
position respect to the plane of the nucleobase: (vi) The vector R (N9···O5') which determines the 
distance of the OH group relative to the base; (vii) The angle β (C4-N9···O5') which defines the angle 
of the OH group relative to the base plane; and (viii) the angle Φ (C1'-N9···O5') which also determines 
the position of the OH group. 
3.2. Conformers and Energetics 
An extensive conformational study of tautomer N1 was carried out through a rotation of the 
exocyclic φ1, φ2, φ3, φ4 and φ5 torsional angles. A detailed collection of the most important 
conformational parameters of these optimized forms is included in Table 2. The conformers were 
classified according to the two ranges of rotation of φ1: conformers A with the φ1 values negative and 
conformers B with φ1 positive. 
Two energy criteria were considered for each conformer: the electronic energy ΔE + ZPE 
correction, and the Gibbs energy ΔG. For the numbering of the conformers in each range of rotation of 
φ1 was followed the ΔE + ZPE criterion. Calculations at different levels, as well as single point 
calculations at the MP2/6-31G(d,p)//B3LYP/6-31G(d,p) level were carried out to confirm the stability 
of the main conformers, Table 2 and Table 3. In general, the stability order remains, although several 
changes are observed. Thus, conformer B2 appears as the most stable one instead of A1 predicted by 
the DFT methods. The % population of the different conformers at 298.15 K (P298.15) and at 273.15 K 
(P273.15) was calculated. It indicates that only confomers A1 (41.5%), B1 (36.1%), B2 (9.6%) and A2 
(8.7%) have importance. The population of the remaining conformers is lower than 1% and thus they 
are not of interest. The temperature effect is not significant. 
By the same methodology, the relative energies of the different conformers have been determined  
in related nucleosides [34,46–48]. The global minimum calculated in these molecules by  
MP2/6-31G(d,p) was in accordance to that found by B3LYP/6-31G(d,p). Thus, our results by B3LYP 
can be considered acceptable. 
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Table 2. The 78 optimum stable conformers calculated in tautomer N1 of acyclovir molecule at the levels: B3LYP/6-311++G(3df,pd) (values 
in bold); MP2/6-31G(d) (values in keys); B3LYP/6-31G(d,p) (values in normal type); O3LYP/6-31G(d,p) (values in brackets); B3PW91/6-
31G(d,p) (values in parenthesis); B3LYP/cc-pVDZ (values in quotation marks) and B972/6-31G(d,p) (values in italic type) level. Distance R 
in Å, torsional angles in degrees, dipole moments in debyes, and energy increments in kcal·mol−1. 
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Table 2. Cont. 















































































A5 5.119 123.3 36.2 −81.4 −71.2 −170.1 60.7 −53.6 5.166 2.952 1.976 
A6 4.839 130.3 50.2 −93.9 −178.3 174.3 −60.6 54.4 7.387 3.870 2.472 
A7 4.342 110.7 69.0 −100.5 73.3 −114.2 −57.0 53.3 4.342 4.088 2.821 
A8 5.314 99.1 61.8 −108.8 70.2 174.4 179.8 123.1 5.490 4.529 3.020 
A9 4.316 72.3 29.9 −100.9 86.9 94.8 −69.7 165.3 8.401 4.540 3.284 
A10 4.317 98.8 29.8 −100.4 87.1 62.4 118.4 −119.6 8.402 4.541 3.295 
A11 4.316 98.8 29.8 −100.5 87.1 94.7 −69.8 165.6 8.403 4.541 3.293 
A12 5.248 97.3 61.6 −107.1 71.8 176.2 −179.4 177.3 6.700 4.778 3.132 
A13 5.137 115.6 37.5 −109.6 69.9 168.6 −72.0 169.7 6.500 4.912 3.329 
A14 3.804 130.6 83.0 −137.1 68.2 −147.3 63.6 64.2 7.916 4.944 4.017 
A15 3.851 140.4 75.7 −114.8 −115.6 140.7 −61.6 63.4 7.669 5.082 3.917 
A16 4.561 120.1 66.8 −112.4 70.5 −178.3 63.9 60.5 7.527 5.103 3.411 
A17 4.400 99.7 34.4 −112.0 67.2 57.8 44.9 48.3 6.225 5.139 4.217 
A18 5.204 119.3 39.3 −110.7 69.8 173.8 −64.3 −63.3 7.512 5.216 3.730 
A19 3.411 68.6 64.3 −92.1 98.3 −114.1 64.4 39.1 7.760 5.354 4.890 
A20 4.387 136.6 10.3 −88.2 158.8 79.4 −71.0 172.6 8.042 5.378 3.969 
A21 3.562 167.7 60.8 −94.2 −126.1 83.2 −74.5 178.0 6.300 5.384 4.494 
A22 4.486 118.5 67.8 −112.8 70.8 −179.7 71.7 −171.9 8.081 5.432 3.764 
A23 5.209 88.5 51.3 −104.5 77.3 91.3 180.0 −69.9 6.218 5.476 3.817 
A24 4.381 115.3 11.5 −102.7 −162.7 −77.3 73.0 −170.7 8.685 5.514 4.179 
A25 4.948 80.5 59.5 −102.5 67.2 74.6 176.3 −68.2 6.425 5.588 4.277 
A26 4.655 80.0 78.1 −99.5 74.6 −104.0 −175.2 72.4 7.000 5.633 4.093 
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Table 2. Cont. 
Conformers R βa Φa φ1 φ2 φ3 φ4 φ5 μ ΔE ΔG 
A27 4.609 83.1 78.2 −102.2 71.5 −107.6 −174.8 179.6 5.473 5.662 4.371 
A28 5.146 128.0 36.4 −81.4 −70.5 −167.5 71.8 −170.7 6.229 5.675 4.396 
A29 4.653 84.8 51.8 −103.7 70.9 −109.1 −174.5 −74.1 6.731 5.845 4.325 
A30 5.235 90.1 49.7 −102.9 80.0 96.4 179.4 −173.8 7.848 5.850 4.085 
A31 4.400 99.7 34.4 −112.0 67.2 57.8 44.9 48.3 6.225 5.890 4.508 
A32 5.220 123.3 38.2 −81.4 −70.2 −172.6 64.6 64.8 4.345 5.909 4.708 
A33 4.415 114.1 12.6 −104.1 −163.1 −74.6 69.3 69.4 7.384 5.917 4.782 
A34 5.955 104.4 31.3 −95.4 179.0 −178.1 179.2 72.9 6.080 6.174 4.503 
A35 5.898 124.0 30.3 −96.6 179.3 179.3 179.9 179.6 6.676 6.195 4.544 
A36 5.956 124.3 31.3 −96.4 179.5 178.1 −179.0 −72.9 7.716 6.254 4.762 
A37 4.565 102.4 34.8 −112.6 66.4 60.5 56.3 −178.8 7.684 6.290 5.085 
A38 4.273 110.2 72.9 −105.8 71.1 −103.2 −66.6 167.8 6.458 6.432 4.855 
A39 4.970 138.6 46.2 −100.0 −179.8 172.1 −72.6 166.4 8.071 6.610 4.755 
A40 5.011 104.7 46.2 −97.2 −179.7 −176.1 72.9 −166.1 7.023 6.779 5.097 
A41 5.030 104.4 48.4 −95.2 179.6 −177.9 64.3 61.5 8.220 7.100 5.519 
A42 5.722 115.4 19.7 −99.3 −176.9 −84.1 −179.2 70.4 6.405 7.372 5.289 
A43 5.350 87.6 45.5 −90.3 138.5 −88.9 −177.6 −70.3 7.007 7.483 7.510 
A44 5.386 92.4 40.2 −91.6 146.1 −91.1 178.5 173.8 7.133 7.627 5.567 
A45 5.699 118.8 18.3 −101.1 −173.8 −84.4 −178.6 176.1 7.994 7.665 5.672 
A46 5.765 120.0 17.5 −101.1 −170.2 −80.2 −173.9 −69.9 6.680 7.684 5.636 
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Table 2. Cont. 

























































































































































































































































































































B6 5.119 123.1 36.3 81.0 70.9 170.1 −60.7 54.1 5.460 2.993 2.035 
B7 4.991 113.3 29.3 107.2 −74.7 −87.7 −56.9 46.5 6.027 3.636 2.427 
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Table 2. Cont. 
Conformers R β a Φ a φ1 φ2 φ3 φ4 φ5 μ ΔE ΔG 
B8 3.582 165.9 56.3 82.7 65.4 73.0 −75.2 178.4 6.463 4.240 3.708 
B9 3.793 70.4 79.1 57.2 68.0 −93.9 −49.8 60.8 5.069 4.263 3.900 
B10 4.325 99.2 29.1 98.3 −88.0 −94.7 69.5 −166.2 8.268 4.496 3.334 
B11 5.318 99.2 61.7 108.3 −70.8 −175.3 179.6 71.1 5.640 4.508 3.006 
B12 5.002 132.0 29.1 77.5 74.7 88.4 57.0 −46.2 5.222 4.791 3.824 
B13 5.138 115.0 37.3 108.2 −70.2 −168.4 71.8 −170.5 6.133 4.845 3.212 
B14 5.246 98.4 61.7 108.6 −71.5 −176.6 179.2 177.1 6.553 4.852 3.244 
B15 5.312 99.2 62.1 108.6 −70.7 −175.8 −178.5 −70.6 7.964 4.893 3.413 
B16 4.407 99.6 33.7 110.2 −68.1 −57.9 −44.6 −48.7 5.939 5.042 4.065 
B17 5.205 118.2 39.0 109.3 −69.6 −172.9 64.6 63.9 7.429 5.101 3.551 
B18 3.562 167.3 60.9 93.8 125.8 −83.0 74.6 −178.0 6.069 5.456 4.582 
B19 5.277 89.9 49.5 103.3 −79.4 −94.8 −179.7 69.2 6.054 5.577 3.960 
B20 4.876 78.3 61.1 101.0 −65.9 −75.2 179.3 −69.0 6.102 5.694 4.494 
B21 5.253 91.0 49.4 103.8 −80.2 −97.6 −178.6 174.8 8.034 5.950 3.922 
B22 4.534 101.8 35.0 112.6 −66.2 −59.3 −55.7 179.6 7.559 6.169 5.032 
B23 3.146 83.0 95.1 73.1 67.3 −116.9 63.5 64.3 5.334 6.305 6.199 
B24 4.610 77.9 77.5 79.0 72.8 −102.2 −173.9 −175.2 5.317 6.617 5.315 
B25 4.365 150.0 33.5 76.4 67.0 59.5 40.5 41.6 5.882 6.677 5.427 
B26 4.618 108.0 52.5 77.2 68.5 −105.1 −173.1 −79.3 5.308 6.689 5.500 
B27 5.184 143.6 51.8 78.9 76.5 89.5 −178.9 −69.4 6.563 6.718 5.374 
B28 4.635 114.4 78.3 79.8 73.8 −101.1 −174.8 72.3 7.031 6.831 5.483 
B29 5.194 141.1 52.7 77.5 74.5 87.3 175.3 68.0 5.203 6.997 5.596 
B30 5.129 142.9 52.3 79.1 76.5 90.0 −179.5 −175.2 7.031 7.015 5.609 
B31 4.964 136.4 32.2 77.2 71.0 78.8 64.1 −178.9 5.033 7.508 6.051 
a Notation used from ref. [49]; b ΔE = 0 = −811.214731 a.u. at B3LYP/6-311++G(3df,pd) level; c ΔE = 0 = −810.723396 a.u. at B3LYP/6-31G(d,p) level;  
d ΔG = 0 = −810.764701 a.u.;e ΔE = 0 = −810.449499 a.u. at O3LYP/6-31G(d,p) level; f ΔE = 0 = −810.419555 a.u. at B3LYP/cc-pVDZ level; g ΔG = 0 = −810.460766 a.u.;  
h ΔE = 0 = −810.760402 a.u. at B3PW91/6-31G(d,p) level; i ΔG = 0 = −810.801662 a.u.; j ΔE = 0 = −810.444324 a.u. at B972/6-31G(d,p) level; k ΔG = 0 = −810.485454 a.u.;  
l ΔE = 0 = −808.643998 a.u. at MP2/6-31G(d) level; m ΔG = 0 = −810.491798 a.u. 
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The conformers differ in general very little in energy. Thus, in our calculations 78 optimized 
conformers were found within the electronic energy range ΔE = 0–8.5 kcal/mol, and Gibbs energy 
range ΔG = 0–6.6 kcal/mol with respect to the global minimum. This range of values of ΔG is smaller 
than that calculated in dG, in dT [50], 0–7 kcal/mol and in dU [31], 0–9 kcal/mol. 
Only four conformers are found within the electronic energy range ΔE = 0–1.0 kcal/mol (by 
criterium of ΔE + ZPE), Table 2, with φ1 −72°/−97° as g− and 70°/96° as g+ by MP2. Among these 
conformers, B1 has the highest dipole moment 6.20 D although very close to that in A1, 6.18 D. These 
conformers are slightly favored in a polarizable environment with water. 
Another seven conformers appear within the electronic energy range ΔE = 1.0–3.0 kcal/mol, three 
values were anti (φ1 ca. −100°) and four syn (φ1 ca. 90°). The anti structures are the expected forms in the 
natural nucleosides that form the nucleotides and polynucleotides in biological systems [33,35,46–48].  
The ratio anti/syn in conformers A is 0.8 in the low-energy group (<3 kcal/mol) but it increases up to 
1.7 in the 3.0–8.5 kcal/mol range. 
The global minimum by DFT methods corresponds to the conformer denoted as A1 (Figure 4) and 
it appears stabilized by an intramolecular H-bond. The optimised bond lengths and natural NBO 
atomic charges on this conformer are collected in Figure 5. This global minimum by criterium of ΔE + 
ZPE agree well to that obtained by criterion of ΔG, but differs of that obtained by MP2/6-31G(d) and 
MP2/6-31G(d,p)//B3LYP/6-31G(d,p), Table 3 and Figure S3. It is because of the small difference in 
energy between both forms A1 and B2. This global minimum in the syn form by MP2 is in accordance 
to that obtained in other nucleosides [33–35] but differs of the anti form expected for the natural 
nucleosides and nucleotides in biological systems [43]. The second most stable conformer is B1 with 
values of φ1 = 70°, φ2 = −152° and φ3 = 94° by MP2.  
Figure 4 shows the six best optimum conformers selected in the two ranges of φ1: three are A  
(A1–A3), and three are B (B1–B3). The values of the intramolecular H-bonds and the most important 
structural angles of each conformer are also included. Figures 6–9 show the distribution of the 78 
optimised conformers according to their energies, exocyclic torsional angles ϕ1–ϕ5, the angles β, Φ, 
and the vector R. The best significant conformers are pointed in these figures. 
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Figure 4. Geometry of the six most optimum conformers selected for each rotation angle 
φ1 determined in A1 conformer of N1 tautomer of acyclovir at B3LYP/6-31G(d,p) level. 
The values of the strongest intramolecular H-bonds are also included.  
 
A 1 B1 B2 
 
A2 B3 A3 
Figure 5. Natural atomic charges and optimum bond lengths in conformer B2 of tautomer 
N1 of acyclovir at B3LYP/6-31G(d,p) and MP2/6-31G(d,p) levels, in fuchsia and green 
colours, respectively. 
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Figure 6. Distribution of the 78 optimum stable calculated conformers at the B3LYP/6-
31G(d,p) level in tautomer N1 of acyclovir according to their exocyclic torsional angle φ1 
and their: (a) relative electronic energy ΔE + ZPE correction; (b) relative Gibbs energy 
ΔG; and (c) the distance R. The most stable conformers of each type are pointed. 
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Figure 7. Distribution of the 78 optimum stable calculated conformers in tautomer N1 of 
acyclovir, according to the values of the exocyclic torsional angles: φ2. φ3. φ4 and φ5 versus 
the angle φ1. 
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Figure 8. Distribution of the 78 optimum stable calculated conformers in tautomer N1 of 
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Figure 9. 3D plots with the relative energies of the 78 optimum stable conformers 
according to the values of the exocyclic torsional angles: φ1. φ2. φ3 and φ4 versus relative 
electronic energy ΔE + ZPE. 
 
 
3.3. Conformational Angle Analysis 
An overall examination of the five exocyclic torsional angles and two bond angles, defining the 
conformational space in tautomer N1 of ACV, leads to conclude the following, Figures 7–9:  
(i) The dihedral angle φ1 presents a bimodal distribution: (−137° ≤ −74°) 47 conformers A (anti) 
and (57° ≤ 113°) 31 conformers B (syn). Anti forms prevail in number over syn ones and cover 
a slight wider range of φ1 values. This anti orientation has been found in the crystal of several 
ϕ2(º) ϕ1(º) 
ϕ3(º) ϕ4(º) 
Pharmaceuticals 2014, 7 713 
 
 
nucleosides [51–53], and it is the form for biological activity [54]. Although, in many 
nucleoside analogues syn and anti forms have similar energy, however, the global minimum 
corresponds in general to the syn form, as in AZT [35]. In purine nucleosides there is relatively 
little restraint to rotation about the N9-C1' bond [55]. In ACV the high population of the anti 
forms and the wider range of φ1 values are factors that facilitate its antiviral activity. The sugar 
ring of the natural nucleoside dG can be mimics by the similar exocyclic angles of ACV. 
(ii) The torsional φ2 angle has a clear bimodal distribution: 65° ≤ φ2 ≤ 180° (49 conformers, 34 are 
A and 15 are B) and –180° ≤ φ2 ≤ −66° (29 conformers, 13 are A and 16 are B), Figure 7. 
(iii) The φ3 angle also has a bimodal conformation: 58° ≤ φ3 ≤ 180° (32 conformers, 22 are A and 
10 are B) and −180° ≤ φ3 ≤ −58° (46 conformers, 25 are A and 21 are B). 
(iv) The φ4 angle has a trimodal distribution: −173° ≤ φ4 ≤ 175° (28 conformers, 16 are A and 12  
are B), 41° ≤ φ4 ≤ 118° (28 conformers, 17 are A and 11 are B), and −75° ≤ φ4 ≤ −45°  
(22 conformers, 14 are A and 8 are B).  
(v) The torsional φ5 angle also has a trimodal distribution: −166° ≤ φ5 ≤ 165° (29 conformers,  
19 A and 10 B), 39° ≤ φ5 ≤ 123° range (29 conformers, 16 A and 13 B), and −120° ≤ φ5 ≤ −46° 
(20 conformers, 12 A and 8 B). 
(vi) In the bond angle β has been observed a regular distribution in the 69° ≤ β ≤ 168° range, Figure 
8. This large range indicates the high flexibility of the chain with multiple O5'H orientations.  
The most stable conformers with ΔE < 1 kcal·mol−1 have the β angle with values between 72° 
and 78°, while the conformers with higher ΔE have some values larger than 140°. 
(vii) The bond Φ angle also shows a regular distribution in the 10° ≤ Φ ≤ 83° range for conformers 
A, and 29° ≤ Φ ≤ 95° for conformers B. The value of this angle appears between 51° and 54° 
for the four best conformers with ΔE < 1 kcal/mol−1. In general, the most stable conformers do 
not have large values of Φ, neither low values. 
Finally, the R vector has a large range of values, between 2.905Å and 5.956 Å, and it determines 
the distance of the OH end of the chain from the base plane.  
3.4. Guanine Moiety 
In the analysis of the six most stable conformers, the base heterocycle has a very small  
non-planarity, in general with torsional angles lower than 1°, with the exception of those involving N3 
and N9 atoms with a value higher than 2°. It is due to the strong intramolecular H5'··N3 hydrogen 
bond which produces a ring deformation around N3. Thus, among the dihedral angles describing the 
base heterocycle nonplanarity, we have defined: ν0 (N1-C2=N3-C4), ν1 (C2=N3-C4=C5), ν2  
(N3-C4=C5-C6), ν3 (N7=C8-N9-C4) and ν4 (C6-N1-C2=N3).  
An analysis of the six most stable conformers (Figure 4) shows that the highest base heterocycle 
nonplanarity corresponds to conformer A2 with the torsional angles ν1 (2.8°), ν2 (−2.3°) and ν0 
(−1.3°). The other conformers show deviations higher than 1° in the following torsional angles: 
Conformer A1 in ν2 (−1.2°) and ν3 (−1.1°), conformer A3 in ν1 (1.5°) and ν2 (−1.3°), conformer B1 in 
ν0 (1.3°) and ν1 (1.1°), and conformer B2 in ν4 (1.2°). 
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Comparing the bond lengths of ACV (conformer A1) with those of dG, it is observed that ACV has 
several bonds of the guanine moiety larger than the corresponding bonds in dG, while in the remaining 
bonds are smaller. The largest difference appears in C4-N3. 
3.5. The Side Chain 
The most important characteristic of the structure of ACV is the conformation of the side chain that 
is attached to N9, which is characterized by the exocyclic torsional angles φ1 to φ5, by the bond angles 
β and Φ that determine the position of the chain from the base, and by the distance R. The bonds along 
this chain can be in trans respect to each other and thus it gives an extended zig-zag structure or, by 
contrast, one or several alternate bonds can be in gauche in such a way that it resembles at least 
partially a portion of the furanose moiety of dG [49,56]. In this last case, it is capable of adopting 
conformations resembling a portion of the pentose ring, a factor which undoubtedly plays an important 
role in their biological activities [57]. Thus, three types of structures appear: two that have the side 
chain partially folded (conformers A and B), and one structure which has all bonds in trans orientation 
and leading to an almost planar zig-zag arrangement [49]. 
3.6. Intramolecular H-Bonds 
Several authors have studied the intramolecular H-bonds in related nucleosides, in special using 
AIM method [58,59]. However, the absence of the furanose ring in ACV reduces largely the number 
of possible H-bonds. Therefore, only two intramolecular H-bonds may be observed in the main 
conformers of ACV: (i) The hydroxyl hydrogen H5'(O5') and the guanine’s position 3 nitrogen atom, 
H5'···N3, and (ii) The hydroxyl hydrogen H5'(O5') and the guanine’s position 2 oxygen atom, 
H5'···O2'. 
Figure 4 shows these types of H-bonds in the six most stable conformers. H-bond (i) appears in 
conformers A1, B1, B2 and A2; while (ii) is observed in conformers B3 and A3 with values of  
2.346 Å and 2.350 Å, respectively. H-bond (i) is stronger than (ii), and it gives a great stability to the 
structure. Thus, the conformers with the H-bond (i) are the most stable, ΔE < 1 kcal·mol−1, while the 
conformers with the H-bond (ii) have higher energy, ΔE > 2 kcal·mol−1. 
3.7. Natural NBO Atomic Charges 
The calculated values in conformer A1 appear collected in Figure 5. The largest negative charge 
corresponds to N2 and O5' atoms, −0.90 and −0.84 e, respectively by MP2 (where e is the charge of an 
electron). The next atom with large negative charge is N1 (ca. −0.7 e). The value of this charge is 
slightly higher than in dG, −0.69 e. The main effect of the NH2 group is a remarkable increment in the 
positive charge on C2, 0.81 e, because of the high negative charge on the amino nitrogen, −0.90 e. 
Consequently, a noticeable increase of the negative charge on N3 is observed, −0.73 e (−0.70 e in dG). 
The electron-rich sites of the guanine moiety are involved in H-bonds, with N3 and O2' acting as 
single acceptors. 
In the nitrogen N9 the negative charge (−0.52 e) is lower than on N1, N3 and N7, but slightly 
higher than in dG. It is because in ACV the bonding to the chain increases the negative charge on N9. 
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The value of the charge on N7 is important because in the neutral form of anti-tumour platinum drugs, 
the platinum atom has a strong preference for nitrogen N7 rather than for oxygen atoms of the base for 
its coordination [51]. Also, the N7 position in DNA is the most open to attack. N1 position is also 
important because when deprotonation of the weakly acid ACV occurs, the metal binding site changes 
to N1, which is the formally deprotonated site [60]. Raman spectra of related nucleosides in H2O 
indicate that the site of deprotonation in basic solutions is N1, while the site of protonation in acidic 
solutions is N3 and N7, the same sites that in its phosphorylated form. These results are useful for 
identification and characterization of its structure in natural occurring biopolymers [61]. 
The negative charge on the oxygen atoms is high, −0.65 e on O2' and −0.69 e on O6. The values in 
O2' and O5' are slightly higher than in dG, by B3LYP −0.603 e and −0.761 e, respectively. By contrast, 
in O6 the negative charge is lower than in dG, −0.592 e. 
C6 is the atom with the highest positive charge, 0.829 e by MP2, in concordance to the high 
negative charge on O6, i.e., it is the most reactive. With a slightly lower value appears C2 (0.812 e), 
and with much lower values H5'(O5'), H1(N1), H2(N2) and H2'(N2). The remaining hydrogen atoms have 
much less positive charge and they are less reactive.  
3.8. Solid State Simulation 
The structure of ACV (CSD code CEHTAK) in the solid state was determined by X-ray  
diffraction [53,60–63]. Birnbaum et al. [49,62] obtained the crystals that belong to monoclinic space 
with three independent molecules (A, B and C), together with two water molecules [49]. Molecules A 
and B have similar conformation while that of molecule C is different, Table 4. In molecules A and B 
the angle ϕ1 and ϕ2 are in the preferred g− form, but in molecule C ϕ2 is in trans. It means that molecules A 
and B showed a partially folded conformation of the side chain, while molecule C appears extended [62]. 
Molecules A and B correspond to conformer A5 in the isolated state, while molecule C is represented by 
conformer A34. Molecules A and B are ca. 3 kcal·mol−1 more stable than molecule C. The difference in 
energy between molecule A and B is small and it is due to the flexibility of the side chains. 
Table 4. A comparison of the most important structural parameters in the dimer and 
tetramer forms calculated at the B3LYP/6-31G(d,p) level in acyclovir molecule with those 
in the crystal. The torsional angles are in degrees and R in Å. 
Solid form R β Φ φ1 φ2 φ3 φ4 φ5 
Dimer     
Molecule A 5.150 127.9 −82.1 −82.1 −70.4 −168.4 71.9 −168.8 
Molecule B 5.148 127.9 −88.8 −88.8 −70.3 −168.1 71.8 −168.9 
Tetramer     
Molecule A 5.148 128.6 −82.3 −82.3 −70.4 −167.3 72.5  −167.4 
Molecule B 5.212 117.2 −80.1 −80.1 −76.3 176.8 64.2 −90.8 
Molecule C 5.110 122.0 158.6 158.6 −71.7 −50.5 60.1 −53.8 
Molecule D 4.313 150.6 −95.3 −95.3 −93.1 −100.2 70.6 −160.4 
X-Ray [62]      
Molecule A   −76.5 −76.9 173.2 60.6  
Molecule B   −74.4 −66.3 −176.2 73.5  
Molecule C   −90.5 −173.3 −171.9 −174.4  
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We have simulated this arrangement through a dimer and tetramer forms, Figure 10. The calculated 
value of the inter- and intramolecular H-bonds distances and the total energy is included in the Figure. 
The calculated bond lengths, bond angles and torsional angles are collected in Tables S1 and S2.  
The simulated structure is tightly bonded but not so tight as it the reported in the crystal. There are four 
donor sites: H1(N1), H2(N2), H2'(N2) and H5', and five possible acceptors: O6, N3, N7, O2' and O5'. 
Figure 10. The optimized dimer and tetramer forms in conformer A1 of acyclovir at the 
B3LYP/6-31G(d,p) level. The H-bonds observed are in Å and the E (RB+HF-LYP) in a. u. 
Dimer -1621.895988 a.u. Tetramer -3243.852071 a.u. 
The dimer, and tetramer forms were built with the most stable conformer A1. In the dimer there are 
two intermolecular H-bonds between the two molecules: N1{in molecule A} and O6{in molecule B} 1.733 Å, 
and O6{in A} and N1{in B} 1.732 Å. The tetramer shows seven H-bonds: (i) two between molecule A 
and B: H(N1){in molecule A} and O6{in molecule B} 1.709 Å, and O6{in molecule A} and H(N1){in molecule B} 
1.847 Å; (ii) There is only a H-bond between molecule B and C: H(O5´){in B} and N3{in C}, 1.945 Å; 
(iii) There are two H-bonds between molecule C and D: H(N1){in molecule C} and O6{in molecule D}, 
1.741 Å, and O6{in C} and H(N1){in D}, 1.792 Å. (iv) At list there are two H-bonds between molecule D 
and B: N7{in molecule D} and H(N2'){in B}, 1.972 Å. 
Comparing the calculated bond lengths and angles of molecule A in the dimer with the X-ray  
data [62], Tables S2 and S3, it is observed the good agreement in the values of our simulated structure. 
The greater differences appear in C4=C5 (0.025 Å), C2-N2 (0.023 Å), C3'-C4' and N1-C6 (0.016 Å), 
and the difference is almost null in C6=O, C5-N7, N7=C8 and C4-N9. A slight larger error is obtained 
when the comparison theory-experiment is carried out with the molecule B of the dimer. This error is 
slight reduced when the comparison is carried out with the simulated molecule A of the tetramer. In 
the angles the difference is almost null, with similar values of all the angles. Only several angles in the 
side chain show some noticeable differences, i.e., C3'-C4'-O5', 4.7°. 
Other four anhydrous forms of ACV and a new hydrate have been characterized by X-ray 
diffraction, with significant differences in the intermolecular H-bonding networks among the ACV 
forms [63–65]. A study of the solution forms of ACV shows that ACV can exist as polymorphic and 
pseudopolymorphic solvates [66]. We have simulated other dimer, trimer and pentamer forms with 
different conformers and collected in Figure S4. 




In the present work we have shown a comprehensive compendium of the possible conformers in 
tautomer N1 of ACV. The geometries and values of the properties presented here appear to the most 
accurate to date. The most important findings of the present work are the following: 
(1) Five tautomers of ACV were identified and fully optimized. At room temperature only 
tautomer N1 (48.1%), OHC (37.7%) and OHT (14.3%) have a noticeable population. It is very 
small in tautomers N3 and N7, less than 0.05%. 
(2) The relative energies of the five tautomers appear related to the dipole moment and to the 
torsional angle φ1. The least stable tautomer N3 in the isolated state has the highest μ and thus, 
it is the most favoured in a polarisable environment with water. 
(3)  In the isolated state the most stable tautomer is N1 by both B3LYP and MP2 methods. In this 
tautomer, and through a rotation of φ1, φ2, φ3, φ4 and φ5 exocyclic torsional angles, 78 
optimized stable conformers were identified, two syn and two anti failing into the 0–1 kcal·mol−1 
ΔE + ZPE energy range. 
(4) The calculated most stable conformer by all DFT levels corresponds to A1, while by MP2 is 
B2. In the nitrogen atoms and in the O2' and O5' oxygen atoms of conformer A1 appear a 
higher reactivity than in the corresponding natural nucleoside deoxyguanosine. 
(5) The distribution of all the conformers according to the ranges of stability of the characteristic 
torsional angles was established. The values obtained indicate the flexible nature of ACV, 
which is higher than dG. An increase of the stability appears when the side chain is near to the 
purine base, with a value of R that fails into 3.925–2.892 Å range, and an angle Φ close to 54°. 
(6) Only two intramolecular H-bonds may be observed in the main conformers of ACV, in contrast 
to the six H-bond types calculated in dG. It leads to a flexibility higher in ACV than in dG. 
(7) The solid state was simulated through a dimer and tetramer forms. An excellent agreement with 
the X-ray crystal data was obtained, which indicates the good accuracy of the theoretical 
methods used. 
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